Comparisons of Prostate Cancer Inhibitors Abiraterone and TOK-001 Binding with CYP17A1 through Molecular Dynamics

Miller, 2011, The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders, Endocr Rev, 32, 81, 10.1210/er.2010-0013 Attard, 2009, Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven, Cancer Res, 69, 4937, 10.1158/0008-5472.CAN-08-4531 Yap, 2008, Targeting CYP17: established and novel approaches in prostate cancer, Curr Opin Pharmacol, 8, 449, 10.1016/j.coph.2008.06.004 Dhir, 2009, Steroid 17α-hydroxylase deficiency: functional characterization of four mutations (A174E, V178D, R440C, L465P) in the CYP17A1 gene, J Clin Endocrinol Metab, 94, 3058, 10.1210/jc.2009-0172 Rosa, 2010, Clinical, genetic and functional characteristics of three novel CYP17A1 mutations causing combined 17α-hydroxylase/17, 20-lyase deficiency, Horm Res Paediatr, 73, 198, 10.1159/000284362 Katsumata, 2010, Novel CYP17A1 mutation in a Japanese patient with combined 17α-hydroxylase /17, 20-lyase deficiency, Metabolism, 59, 275, 10.1016/j.metabol.2009.07.024 Ergun-Longmire, 2006, Two novel mutations found in a patient with 17α-hydroxylase enzyme deficiency, J Clin Endocrinol Metab, 91, 4179, 10.1210/jc.2006-0469 Sahakitrungruang, 2009, Novel P450c17 mutation H373D causing combined 17α-hydroxylase /17, 20-lyase deficiency, J Clin Endocrinol Metab, 94, 3089, 10.1210/jc.2009-0645 Biason-Lauber, 2000, 17 α-hydroxylase/17,20-lyase deficiency as a model to study enzymatic activity regulation: role of phosphorylation, J Clin Endocrinol Metab, 85, 1226 Lee-Robichaud, 2004, The cationic charges on Arg347, Arg358 and Arg449 of human cytochrome P450c17 (CYP17) are essential for the enzyme’s cytochrome b5-dependent acyl-carbon cleavage activities, J Steroid Biochem Mol Biol, 92, 119, 10.1016/j.jsbmb.2004.07.005 Gupta, 2001, Pitfalls in characterizing P450c17 mutations associated with isolated 17, 20-lyase deficiency, J Clin Endocrinol Metab, 86, 4416, 10.1210/jcem.86.9.7812 Tiosano, 2008, Metabolic evidence for impaired 17α-hydroxylase activity in a kindred bearing the E305G mutation for isolate 17, 20-lyase activity, Eur J Endocrinol, 158, 385, 10.1530/EJE-07-0712 Arlt, 2002, Molecular evolution of adrenarche: structural and functional analysis of p450c17 from four primate species, Endocrinology, 143, 4665, 10.1210/en.2002-220456 Swart, 2010, A single amino acid residue, Ala 105, confers 16α-hydroxylase activity to human cytochrome P450 17α-hydroxylase/17, 20-lyase, J Steroid Biochem Mol Biol, 119, 112, 10.1016/j.jsbmb.2009.12.014 Petrunak, 2014, Structures of human steroidogenic cytochrome P450 17A1 with substrates, J Biol Chem, 289, 32952, 10.1074/jbc.M114.610998 Vasaitis, 2011, CYP17 inhibitors for prostate cancer therapy, J Steroid Biochem Mol Biol, 125, 23, 10.1016/j.jsbmb.2010.11.005 DeVore, 2012, Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001, Nature, 482, 116, 10.1038/nature10743 de Bono, 2011, Abiraterone and increased survival in metastatic prostate cancer, New Engl J Med, 364, 1995, 10.1056/NEJMoa1014618 Loriot, 2013, Antitumour activity of abiraterone acetate against metastatic castration- resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100), Ann Oncol, 24, 1807, 10.1093/annonc/mdt136 Ferraldeschi, 2013, Agents that target androgen synthesis in castration-resistant prostate cancer, Cancer J, 19, 34, 10.1097/PPO.0b013e31827e0b6f Pia, 2013, Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone, Cancer Treat Rev, 39, 966, 10.1016/j.ctrv.2013.03.003 Attard, 2012, Clinical and biochemical consequnces of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer, J Clin Endocrinol Metab, 97, 507, 10.1210/jc.2011-2189 Vincent, 2015, Discovery and development of galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer, J Med Chem, 58, 2077, 10.1021/jm501239f Handratta, 2005, Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model, J Med Chem, 48, 2972, 10.1021/jm040202w Vasaitis, 2008, Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17- (1H-benzimidazole-1-yl) androsta-5,16-diene in prostate cancer, Mol Cancer Ther, 7, 2348, 10.1158/1535-7163.MCT-08-0230 Bruno, 2011, Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model, Steroids, 76, 1268, 10.1016/j.steroids.2011.06.002 Purushottamachar, 2013, Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer, J Med Chem, 56, 4880, 10.1021/jm400048v Guex, 1997, SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling, Electrophoresis, 18, 2714, 10.1002/elps.1150181505 Pettersen, 2004, UCSF Chimera—a visualization system for exploratory research and analysis, J Comput Chem, 25, 1605, 10.1002/jcc.20084 Koziara, 2014, Testing and validation of the Automated Topology Builder (ATB) version 2.0: prediction of hydration free enthalpies, J Comput Aided Mol Des, 28, 221, 10.1007/s10822-014-9713-7 Hess, 2008, GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation, J Chem Theory Comp, 4, 435, 10.1021/ct700301q van Gunsteren, 1996, Simulation, Biomolecular Fraternali, 1996, An efficient mean solvation force model for use in molecular dynamics simulations of proteins in aqueous solution, J Mol Biol, 256, 939, 10.1006/jmbi.1996.0139 Byrd, 1995, A limited memory algorithm for bound constrained optimization, SIAM J Sci Stat Comput, 16, 1190, 10.1137/0916069 Zhu, 1997, L-BFGS-B: algorithm 778: L-BFGS-B, FORTRAN routines for large scale bound constrained optimization, ACM Trans Math Softw, 23, 550, 10.1145/279232.279236 Berendsen, 1984, Molecular -dynamics with coupling to an external bath, J Chem Phys, 81, 3684, 10.1063/1.448118 Hess, 1997, LINCS: a linear constraint solver for molecular simulations, J Comput Chem, 18, 1463, 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H Dargen, 1993, Particle mesh Ewald: an N⋅log (N) method for Ewald sums in large systems, J Chem Phys, 98, 10089, 10.1063/1.464397 DeLano, 2002 Xiao, 2011, Detailed regulatory mechanism of the interaction between ZO-1PDZ2 and Connexin43 revealed by MD simulations, PLoS One, 6, 21527, 10.1371/journal.pone.0021527 Xiao, 2010, Mechanism of Ser88 phosphorylation induced dimer dissociation in dynein light chain LC8, J Phys Chem B, 114, 15663, 10.1021/jp1048869 Jacoby, 2013, Differential effects of galeterone, abiraterone, orteronel, and ketoconazole on CYP17 and steroidogenesis, ASCO Meeting Abstr, 31, 184